Polares Medical Secures $50M Series C to Advance Mitral Valve Therapy…

Team S · 2026-03-05T14:41:16.000Z

Switzerland-based medtech company Polares Medical has raised $50 million in a Series C funding round to accelerate the development of its innovative cardiac treatment technology designed for patients suffering from mitral regurgitation, a serious heart valve disease affecting millions globally. The company is developing a transcatheter therapy aimed at improving treatment options for patients who cannot benefit from existing minimally invasive procedures. Polares Medical is building the MRace Posterior Leaflet Replacement system, a novel implant designed to restore the function of the mitral valve by replacing the posterior leaflet - one of the two key tissues responsible for preventing blood from flowing backward in the heart. The technology aims to expand treatment access for patients whose anatomy makes conventional therapies difficult or ineffective. The $50 million Series C financing round was oversubscribed and saw participation from DC Global Ventures, Lumination Partners, existing investors, and a new undisclosed strategic investor. The fresh capital will be used to support ongoing clinical trials of the MRace system across the United States, Europe, and Australia, helping the company accelerate global development and regulatory progress. With more than 70 patients already implanted with the MRace system during clinical studies, early results have demonstrated encouraging safety and efficacy outcomes. The new funding will allow Polares to expand clinical trials and strengthen its position in the rapidly evolving structural heart treatment market.

Member Login Get Access

Polares Medical Secures $50M Series C to Advance Mitral Valve Therapy… | Newnex